Who are clarithromycin, rifabutin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clarithromycin-rifabutin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

clarithromycin, rifabutin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

clarithromycin, rifabutin (clarithromycin, rifabutin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic and rifamycin antibiotic combination. Area: Infectious Disease.

marketed Macrolide antibiotic and rifamycin antibiotic combination Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

clarithromycin, rifabutin (clarithromycin, rifabutin) — The University of Texas Health Science Center at Tyler. Clarithromycin and rifabutin are macrolide and rifamycin antibiotics that inhibit bacterial protein synthesis and RNA-dependent RNA polymerase, respectively, used together to treat mycobacterial infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
clarithromycin, rifabutin TARGET	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic and rifamycin antibiotic combination class)

The University of Texas Health Science Center at Tyler · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). clarithromycin, rifabutin — Competitive Intelligence Brief. https://druglandscape.com/ci/clarithromycin-rifabutin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab